Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group

• Published in: Cancers Vol. 15; no. 1; p. 244
• Main Authors: Nguyen, Nam P, Ali, Ahmed, Vinh-Hung, Vincent, Gorobets, Olena, Chi, Alexander, Mazibuko, Thandeka, Migliore, Natália, Vasileiou, Maria, Lehrman, David, Mohammadianpanah, Mohammad, Javadinia, Seyed Alireza, Loganadane, Gokoulakrichenane, Basu, Trinanjan, Bose, Satya, Karlsson, Ulf, Giap, Huan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.12.2022; MDPI
• Subjects: Aged patients; Apoptosis; Biomarkers; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Dendritic cells; Disease; Ethnicity; Gene expression; Geriatrics; Hypotheses; Immune checkpoint inhibitors; Immune system; Immunotherapy; Inflammation; Kinases; Lymphocytes; Lymphocytes T; Medical prognosis; Melanoma; Metastases; Metastasis; Methods; Morbidity; Patients; PD-L1 protein; Radiation therapy; Radiosurgery; Remission; Sarcoma; Surgery; Toxicity; Tumor cells; Tumor necrosis factor-TNF; Tumors; United States; older; CPI; oligometastases; SBRT; cancer patients
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15010244

The standard of care for metastatic disease is systemic therapy. A unique subset of patients with limited metastatic disease defined as distant involvement of five anatomic sites or less (oligometastases) have a better chance of remission or improved survival and may benefit from local treatments such as surgery or stereotactic body radiotherapy (SBRT). However, to prevent further spread of disease, systemic treatment such as chemotherapy, targeted therapy, and hormonal therapy may be required. Older patients (70 years old or above) or physiologically frail younger patients with multiple co-morbidities may not be able to tolerate the conventional chemotherapy due to its toxicity. In addition, those with a good performance status may not receive optimal chemotherapy due to concern about toxicity. Recently, immunotherapy with checkpoint inhibitors (CPI) has become a promising approach only in the management of program death ligand 1 (PD-L1)-positive tumors. Thus, a treatment method that elicits induction of PD-L1 production by tumor cells may allow all patients with oligometastases to benefit from immunotherapy. In vitro studies have demonstrated that high dose of radiotherapy may induce formation of PD-L1 in various tumors as a defense mechanism against inflammatory T cells. Clinical studies also corroborated those observations. Thus, SBRT, with its high precision to minimize damage to normal organs, may be a potential treatment of choice for older patients with oligometastases due to its synergy with immunotherapy. We propose a protocol combining SBRT to achieve a minimum radiobiologic equivalent dose around 59.5 Gy to all tumor sites if feasible, followed four to six weeks later by CPI for those cancer patients with oligometastases. All patients will be screened with frailty screening questionnaires to identify individuals at high risk for toxicity. The patients will be managed with an interdisciplinary team which includes oncologists, geriatricians, nurses, nutritionists, patient navigators, and social workers to manage all aspects of geriatric patient care. The use of telemedicine by the team may facilitate patient monitoring during treatment and follow-up. Preliminary data on toxicity, local control, survival, and progression-free survival may be obtained and serve as a template for future prospective studies.